Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMVT-1402 Long-Term Extension Study in Graves' Disease
NCT07286006Phase 2Enrolling by invitation
- Sponsor
- Immunovant, Inc.
- Start
- Jan 2026
- Primary completion
- Mar 2030
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of IMVT-1402 in Graves' disease, sponsored by Immunovant, Inc.. Started Jan 2026; status: enrolling by invitation.
02
Drugs
IMVT-1402
03
Conditions
Graves' disease
Beyond the preview
Go deeper on NCT07286006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07286006.